Skip to main content
. 2021 Jun 5;36:100933. doi: 10.1016/j.eclinm.2021.100933

Fig. 5.

Fig. 5

A. Title: Among Black patients, cardiovascular death or HF hospitalizations/urgent visits was significantly lower in the SGLT2 inhibitor group.Legend: In patients with HF who were Black, there was a significant 37% relative risk reduction in the composite of cardiovascular death or HF hospitalizations/urgent visits among those treated with SGLT2 inhibitors compared with placebo (OR 0•63; 95% CI 0•40–0•99). B. Title: Among White patients, cardiovascular death or HF hospitalizations/urgent visits was significantly lower in the SGLT2 inhibitor group. Legend: In patients with HF who were White, there was a 23% relative risk reduction in the composite of cardiovascular death or HF hospitalizations/urgent visits among those treated with SGLT2 inhibitors compared with placebo (OR 0•77; 95% CI 0•65–0•91).